No connection

Search Results

ZVRA

NEUTRAL
$10.11 Live
Zevra Therapeutics, Inc. · NASDAQ
Target $22.78 (+125.3%)
$7.04 52W Range $13.16
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$597.65M
P/E
7.49
ROE
85.7%
Profit margin
78.2%
Debt/Equity
0.41
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
75%
ZVRA presents a contradictory profile characterized by a weak Piotroski F-Score of 2/9, indicating poor fundamental health trends, contrasted with explosive revenue growth of 183.40%. While the current price of $10.11 is slightly above the Graham Number ($9.09) and Intrinsic Value ($9.45), the low P/E of 7.49 suggests a valuation disconnect. The company is transitioning from a history of heavy losses to sporadic profitability, but the negative ROA and low F-Score signal significant underlying financial instability. The outlook is balanced between high-growth biotech potential and poor deterministic health metrics.

Key Strengths

Explosive YoY revenue growth of 183.40%
Very low P/E ratio (7.49) relative to sector averages
Strong short-term liquidity with a Current Ratio of 5.68
High current profit margins (78.17%)
Significant analyst price target upside ($22.78)

Key Risks

Weak Piotroski F-Score (2/9) indicating deteriorating financial strength
Extremely high PEG ratio (10.67) suggesting overvaluation relative to sustainable growth
Negative Return on Assets (ROA: -1.14%) despite high ROE
Highly volatile earnings history with frequent misses over 25 quarters
Low insider sentiment score (40/100)
AI Fair Value Estimate
Based on comprehensive analysis
$9.27
-8.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
38
Weak
Value
60
Future
80
Past
30
Health
20
Dividend
0
AI Verdict
Speculative Growth
Key drivers: Revenue acceleration, Fundamental health decay, Valuation gap
Confidence
80%
Value
60/100

P/E 7.49, Graham Number $9.09

Positives
  • Low P/E ratio
  • Price close to Graham Number
Watchpoints
  • High PEG ratio
  • Trading at a slight premium to intrinsic value
Future
80/100

Revenue Growth 183.40%

Positives
  • Triple-digit revenue growth
  • Aggressive analyst price targets
Watchpoints
  • Unpredictable earnings trajectory
Past
30/100

25-quarter earnings track record

Positives
  • Recent shift toward positive EPS
Watchpoints
  • Long history of earnings misses
  • High volatility in quarterly results
Health
20/100

Piotroski F-Score 2/9

Positives
  • Low Debt/Equity (0.41)
  • High Current Ratio
Watchpoints
  • Piotroski F-Score 2/9
  • Negative ROA
Dividend
0/100

Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$10.11
Analyst Target
$22.78
Upside/Downside
+125.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ZVRA and closest competitors.

Updated 2026-04-23
ZVR
Zevra Therapeutics, Inc.
Primary
5Y
+8.1%
3Y
+76.1%
1Y
+39.5%
6M
-5.3%
1M
+10.5%
1W
-2.8%
ESP
Esperion Therapeutics, Inc.
Peer
5Y
-91.3%
3Y
+70.1%
1Y
+119.8%
6M
-9.3%
1M
-23.4%
1W
-10.7%
RIG
Rigel Pharmaceuticals, Inc.
Peer
5Y
-6.8%
3Y
+165.8%
1Y
+92.5%
6M
+16.1%
1M
+27.5%
1W
+11.1%
BVS
Bioventus Inc.
Peer
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
IRW
Ironwood Pharmaceuticals, Inc.
Peer
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
7.49
Forward P/E
6.65
PEG Ratio
10.67
P/B Ratio
3.72
P/S Ratio
5.61
EV/Revenue
4.38
EV/EBITDA
-2602.06
Market Cap
$597.65M

Profitability

Profit margins and return metrics

Profit Margin 78.17%
Operating Margin 27.3%
Gross Margin 84.52%
ROE 85.66%
ROA -1.14%

Growth

Revenue and earnings growth rates

Revenue Growth +183.4%
Earnings Growth N/A
Q/Q Revenue Growth +183.36%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.41
Low debt
Current Ratio
5.68
Strong
Quick Ratio
5.46
Excellent
Cash/Share
$3.25

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
95.5%
Op. Margin
27.3%
Net Margin
35.6%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.84x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-03-09
$0.19
+322.2% surprise
2025-11-05
$-0.01
+50.0% surprise
2025-08-12
$-0.06
-104.3% surprise

Healthcare Sector Comparison

Comparing ZVRA against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
P/E Ratio
7.49
This Stock
vs
77.48
Sector Avg
-90.3% (Discount)
Return on Equity (ROE)
85.66%
This Stock
vs
-89.9%
Sector Avg
-195.3% (Below Avg)
Profit Margin
78.17%
This Stock
vs
-16.4%
Sector Avg
-576.7% (Weaker)
Debt to Equity
0.41
This Stock
vs
2.71
Sector Avg
-84.9% (Less Debt)
Revenue Growth
183.4%
This Stock
vs
126.74%
Sector Avg
+44.7% (Fast Growth)
Current Ratio
5.68
This Stock
vs
4.53
Sector Avg
+25.3% (Stronger)

Similar Companies

Peer comparison within the same industry

ZVRA Zevra Therapeutics, Inc.
NEUTRAL
Mkt Cap
$598M
P/E
7.5
ROE
85.7%
Price
$10.11
ESPR Esperion...
NEUTRAL
Mkt Cap
$598M
P/E
-
ROE
-%
Price
$2.33
 Compare with ZVRA
RIGL Rigel...
BULLISH
Mkt Cap
$599M
P/E
1.7
ROE
185.9%
Price
$32.43
 Compare with ZVRA
BVS Bioventus Inc.
BEARISH
Mkt Cap
$596M
P/E
26.8
ROE
13.2%
Price
$8.84
 Compare with ZVRA
IRWD Ironwood...
BEARISH
Mkt Cap
$592M
P/E
24.2
ROE
-%
Price
$3.63
 Compare with ZVRA

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-20

ZVRA filed a definitive proxy statement on April 20, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

8-K
8-K
2026-03-16
8-K
8-K
2026-03-09
10-K
10-K
2026-03-09

ZVRA filed its annual 10-K on March 9, 2026, which includes comprehensive sections on its business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2025-12-17
8-K
8-K
2025-12-02
8-K
8-K
2025-11-20
10-Q
10-Q
2025-11-05

ZVRA filed its quarterly 10-Q report on November 5, 2025. The provided excerpt indicates the inclusion of a risk factors section, although specific financial highlights and detailed risk descriptions were not available in the text.

8-K
8-K
2025-11-05

Zevra Therapeutics filed an 8-K on November 5, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-08-12

Zevra Therapeutics filed an 8-K on August 12, 2025, likely to announce its second-quarter financial results.

10-Q
10-Q
2025-08-12
8-K
8-K
2025-05-29
10-Q
FORM 10-Q
2025-05-13
8-K
FORM 8-K
2025-05-13
8-K
8-K
2025-04-07
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
9 analysts
BTIG
2026-03-16
init
Buy
Canaccord Genuity
2025-11-06
Maintains
Buy Buy
Cantor Fitzgerald
2025-11-06
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning ZVRA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile